Successful End-of-Phase 2 (EoP2) meeting with U.S. Food and Drug Administration (FDA) provides a potential path to New Drug Application (NDA) submission for BNC210 for post-traumatic stress disorder (PTSD) with a single Phase 3 trialCompany received favorable FDA feedback on the Phase 3 study design and safety monitoring plans required for registrationCompany plans to initiate the Phase 3 program in Q4 2024A conference call and webcast presentation to discuss the outcomes will be held today at 8:00 a.m. ET, ...

文章核心观点 - 公司在第二季度创下多项财务纪录,包括收入、净利润和经调整EBITDA等指标均创新高 [1][2][3][4][5][6] - 公司两个业务分部均实现了两位数的有机增长,其中联邦解决方案分部增长27%,关键基础设施分部增长15% [10][15] - 公司经调整EBITDA利润率有所提升,联邦解决方案分部为10.4%,关键基础设施分部为7.0% [11][16] - 公司在第二季度获得了多个重大合同,包括价值4.6亿美元的导弹防御系统合同和价值1.6亿美元的沙特阿拉伯合同 [19][20] - 公司宣布将以约2亿美元收购BlackSignal Technologies,以拓展客户群和增强电子战及网络攻击能力 [22] - 公司全年财务指引均有所上调,反映了良好的经营表现和未来的乐观前景 [23][24][25] 联邦解决方案分部 - 该分部第二季度收入增长30%,主要得益于最近合同的增长和现有合同的执行 [10] - 该分部经调整EBITDA增长20%,但利润率有所下降,主要是由于上年同期获得了2000万美元的非经常性奖励性费用 [11] 关键基础设施分部 - 该分部第二季度收入增长15%,主要得益于中东和北美基础设施业务的增长 [15] - 该分部经调整EBITDA增长46%,利润率提升150个基点至7.0%,主要得益于高毛利项目的增长和运营表现的改善 [16]

WAYNE, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Ringer™ Perfusion Balloon Catheter (PBC), the only commercially available Percutaneous Transluminal Coronary Angioplasty (PTCA) perfusion balloon.1 The Ringer™ PBC is a rapid-exchange 0.014" compatible catheter with a unique helical balloon at its working end. When inflated, this balloon approximates ...

WAUKESHA, Wisc., July 31, 2024 (GLOBE NEWSWIRE) -- Generac Holdings Inc. (NYSE:GNRC) ("Generac" or the "Company"), a leading global designer and manufacturer of energy technology solutions and other power products, today reported financial results for its second quarter ended June 30, 2024 and provided an update on its outlook for the full-year 2024. Second Quarter 2024 Highlights Net sales were $998 million during the second quarter of 2024 as compared to $1.00 billion in the prior-year second quarter. Cor ...

BEIJING, July 31, 2024 (GLOBE NEWSWIRE) -- KE Holdings Inc. ("Beike" or the "Company") (NYSE:BEKE, HKEX: 2423))), a leading integrated online and offline platform for housing transactions and services, today announced that it will report its unaudited financial results for the second quarter of 2024 before the U.S. market opens on Monday, August 12, 2024. The Company's management will hold an earnings conference call at 8:00 A.M. Eastern Time on Monday, August 12, 2024 (8:00 P.M. Beijing Time on Monday, Aug ...

文章核心观点 - 公司IDEAYA Biosciences与Biocytogen Pharmaceuticals达成合作,获得一款潜在的首创B7H3/PTK7双特异性抗体偶联药物(BsADC)的全球独家许可选择权 [1][2][5] - 该BsADC在肺癌、结直肠癌和头颈癌等多种实体瘤中表达率较高,有望作为单药治疗和与IDEAYA公司的DNA损伤修复(DDR)管线产品如IDE161(PARG抑制剂)联合使用 [3][5][7] - 预计于2024年下半年提名该BsADC的开发候选化合物 [7] 公司信息 - IDEAYA Biosciences是一家精准医疗肿瘤公司,专注于靶向治疗药物的发现和开发 [8] - Biocytogen是一家专注于创新抗体药物研发的全球生物技术公司,拥有多种基因编辑平台和丰富的抗体发现经验 [9][10] 交易条款 - 根据协议,Biocytogen将获得IDEAYA的前期费用和里程碑付款,总额最高可达4.065亿美元,包括1亿美元的开发和监管里程碑 [6] - 此外,Biocytogen还将获得单位数字百分比的特许权使用费 [6]

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Lotus Technology Inc. ("Lotus Tech" or "the Company") (NASDAQ:LOT), a leading global luxury electric vehicle maker, has today announced it becomes a finalist in two categories in Reuters Sustainability Awards 2024. Reuters Sustainability Awards, now in their 14th year, are the world's leading awards celebrating leadership in sustainable business. These awards recognize strategies that deliver tangible impacts on business, society, and the environment. The nominati ...

Net sales of $984 million decreased (4.2%), organic sales decreased (2.3%)GAAP gross margin of 51.9%, GAAP net loss of ($4) million or loss per share of ($0.02)Adjusted EBITDA margin of 17.5%, adjusted EPS of $0.49Revised FY24 outlook: organic sales down (1%) to flat (previously flat to up 1.5%); adjusted EPS of $1.96 to $2.02 (previously $2.00 to $2.10)Company repurchased $150 million of its common stock in Q2 2024; expects to repurchase $100 million of its common stock in Q3 2024Second phase of transforma ...

Conference Call and Webcast Today at 4:30 PM EDT SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced that the Company will host an investor conference call and webcast today at 4:30 PM EDT to share topline data results from the Phase 2 ASPEN-06 clinical trial evaluating evorpacept for the treatment of advanced HER2-p ...

MAHWAH, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Radware® (NASDAQ:RDWR), a leading provider of cyber security and application delivery solutions, today announced the launch of its proprietary Radware EPIC-AI™, which adds multiple layers of AI-powered intelligence and capabilities across its application and network security solutions and services. EPIC-AI infuses state-of-the-art AI and generative AI algorithms across Radware's security solutions to deliver precise, hands-free, consistent protections across c ...